Compare YORW & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YORW | ALT |
|---|---|---|
| Founded | 1816 | 1997 |
| Country | United States | United States |
| Employees | 104 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 421.5M |
| IPO Year | 1994 | 2005 |
| Metric | YORW | ALT |
|---|---|---|
| Price | $31.26 | $2.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $34.00 | $17.67 |
| AVG Volume (30 Days) | 189.6K | ★ 4.6M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $77,488,000.00 | $41,000.00 |
| Revenue This Year | $11.78 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $95.18 | ★ N/A |
| Revenue Growth | 3.37 | ★ 105.00 |
| 52 Week Low | $28.26 | $2.56 |
| 52 Week High | $34.30 | $6.44 |
| Indicator | YORW | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 43.39 |
| Support Level | $30.96 | $2.62 |
| Resistance Level | $32.83 | $3.15 |
| Average True Range (ATR) | 0.72 | 0.17 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 70.25 | 7.14 |
The York Water Co is the investor-owned water utility in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. The company also owns and operates three wastewater collection systems and twelve wastewater collection and treatment systems. The company operates within its franchised water and wastewater territory, which covers portions of municipalities within four counties in south-central Pennsylvania. It provides services to diversified, manufacturing such items as fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergent, barbells, and motorcycles.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.